Post Profile






Exploring Company Contributions To The Origination Of New Medicines

A new FDA approval marks a major milestone in the biopharmaceutical business; relatively few biopharma companies are ever able to lay claim to having discovered, developed, or marketed a recently approved medicine. As of mid-October, the FDA has approved 17 new medical entities in 2016. Earlier this year, John Carroll at [...]
read more

share

Related Posts


Shire Announces FDA Approval Of VPRIV(TM) (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease

Health : Medical News Today

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for VPRIV, a human cell line derived enzyme replacement t...

Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate

Health : Newswise Medical News

Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") today announced that the U.S. Food and Drug Administration (FDA) approved Ferric Citrate (formerly known as Zerenex) for the control of serum phosphorus levels in patients...

Vitreomacular Traction Treatment JETREA(R) Gains EU Approval

Health : Medical News Today

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, has announced that the European Commission has approved JETREA(R) (ocripla...

Health Canada approves JETREA® for the treatment of symptomatic vitreomacular adhesion

Health : Medical News Today

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, has announced that Health Canada has approved JETREA(R) (ocriplasmin) for ...

Kite Pharma's CEO On Bringing Cancer-Killing T-cells To The FDA

Business & Finance : Forbes: Business

Kite Pharma CEO Arie Belldegrun feels his company is inching closer to its goal of being the first to file for FDA approval of an engineered T-cell treatment for cancer. But investors have been asking some tough questions.

Comments


Copyright © 2016 Regator, LLC